CFDE Data Portal | Search IDI2-AS1

	Label	Description
	IDI2-AS1 associations Collection (Entity type)	Associations for IDI2-AS1_associations
	IDI2-AS1 associations.tsv File (Entity type)	A file from IDG as part of the Harmonizome project
	IDI2-AS1 Gene (Entity type)	ENSG00000232656 - IDI2 antisense RNA 1
	GSE113655 phenol 1 v 2 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE111247 temozolomide LN-308 14 v 12 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE238116 EGR1 HCC overexpression MHCC97-H PLC-PRF-5 3 v 0 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE176403 GSE176404 LSD1 inhibition 1 v 4 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE77108 saha 0 v 1 human dn Gene Set (Entity type)	A Gene Set from LINCS
	GSE146358 dopamine 5 v 2 human up Gene Set (Entity type)	A Gene Set from LINCS
	GSE99875 everolimus 2 v 0 human dn Gene Set (Entity type)	A Gene Set from LINCS

IDI2-AS1 associations

Associations for IDI2-AS1_associations

IDI2-AS1 associations.tsv

A file from IDG as part of the Harmonizome project

IDI2-AS1

ENSG00000232656 - IDI2 antisense RNA 1

GSE113655 phenol 1 v 2 human dn

A Gene Set from LINCS

GSE111247 temozolomide LN-308 14 v 12 human dn

A Gene Set from LINCS

GSE238116 EGR1 HCC overexpression MHCC97-H PLC-PRF-5 3 v 0 human up

A Gene Set from LINCS

GSE176403 GSE176404 LSD1 inhibition 1 v 4 human up

A Gene Set from LINCS

GSE77108 saha 0 v 1 human dn

A Gene Set from LINCS

GSE146358 dopamine 5 v 2 human up

A Gene Set from LINCS

GSE99875 everolimus 2 v 0 human dn

A Gene Set from LINCS

DISPLAY PER PAGE

@CFDE Workbench 2026

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

The CFDE Workbench is actively being developed and maintained by the CFDE Data Resource Center (DRC).The DRC is funded by OT2OD036435 from the Common Fund at the National Institutes of Health.

@CFDE Workbench 2026

This repository is under review for potential modification in compliance with Administration directives.